Tamoxifen enhances myoepithelial cell suppression of human breast carcinoma progression in vitro by two different effector mechanisms

Cancer Letters

Volumn 157, Issue 2, 2000, Pages 133-144

  Shao, Zhi Ming ^a   Radziszewski, Waldemar J ^a   Barsky, Sanford H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ER ; Maspin; Myoepithelial cell; Nitric oxide; Tamoxifen; Tumor suppression

Indexed keywords

ANTIESTROGEN; ESTRADIOL; HORMONE; MASPIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TAMOXIFEN;

ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EXPOSURE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ESTROGEN ACTIVITY; HUMAN; HUMAN CELL; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, NORTHERN; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL DIVISION; DISEASE PROGRESSION; EPITHELIAL CELLS; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PRECIPITIN TESTS; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERINE PROTEINASE INHIBITORS; SERPINS; TAMOXIFEN; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0034285093     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(00)00466-3     Document Type: Article

References (32)

1. Sternlicht M.D., Kedeshian P., Shao Z-M., Safarians S., Barsky S.H. The human myoepithelial cell is a natural tumor suppressor. Clin. Cancer Res. 3:1997;1949-1958.
2. Sternlicht M.D., Barsky S.H. The myoepithelial defense: a host defense against cancer. Med. Hypotheses. 48:1997;37-46.
3. Shao Z.M., Nguyen M., Alpaugh M.L., O'Connell J.T., Barsky S.H. The human myoepithelial cell exerts antiproliferative effects on breast carcinoma cells characterized by p21WAF1/CIP1 induction, G2/M arrest, and apoptosis. Exp. Cell Res. 241:1998;394-403.
4. Barsky S.H., Shao Z.M., Bose S. Should DCIS be renamed carcinoma of the ductal system? Breast J. 5:1999;70-72.
5. Sternlicht M.D., Safarians S., Calcaterra T.C., Barsky S.H. Establishment and characterization of a novel human myoepithelial cell line and matrix-producing xenograft from a parotid basal cell adenocarcinoma. In Vitro Cell. Dev. Biol. 32:1996;550-563.
6. Sternlicht M.D., Safarians S., Rivera S.P., Barsky S.H. Characterizations of the extracellular matrix and proteinase inhibitor content of human myoepithelial tumors. Lab. Invest. 74:1996;781-796.
7. Nguyen M., Lee M.C., Wang J.L., Tomlinson J.S., Alpaugh M.L., Barsky S.H. The human myoepithelial cell displays a multifaceted anti-angiogenic phenotype. Oncogene. 19:2000;3449-3459.
8. Bodis S., Siziopikou K.P., Schnitt S.J., Harris J.R., Fisher D.E. Extensive apoptosis in ductal carcinoma in situ of the breast. Cancer. 77:1996;1831-1835.
9. Albini A., Iwamoto Y., Kleinman H.K., Martin G.R., Aaronson S.A., Kozlowski J.M., McEwan R.N. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res. 47:1987;3239-3245.
10. Feinberg A.P., Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem. 132:1983;6-13.
11. Ding A.H., Nathan C.F., Stuehr D.J. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J. Immunol. 141:1988;2407-2412.
12. Dotzlaw H., Leygue E., Watson P.H., Murphy L.C. Expression of estrogen receptor-beta in human breast tumors. J. Clin. Endocrinol. Metab. 82:1997;2371-2374.
13. Cavenee W.K. A siren song from tumor cells. J. Clin. Invest. 91:1993;3-7.
14. Liotta L.A., Steeg P.S., Stetler-Stevenson W.G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 64:1991;327-336.
15. Safarians S., Sternlicht M.D., Yamanishi D.T., Love S.M., Barsky S.H. Human breast cancer progression can be regulated by dominant trans-acting factors in somatic cell hybridization studies. Cancer Res. 56:1996;3560-3569.
16. Folkman J., Klagsburn M. Angiogenic factors. Science. 235:1987;442-447.
17. Cornil I., Theodorescu D., Man S., Herlyn M., Jambrosic J., Kerbel R.S. Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc. Natl. Acad. Sci. USA. 88:1991;6028-6032.
18. Sheng S., Truong B., Fredrickson D., Wu R., Pardee A.B., Sager R. Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin. Proc. Natl. Acad. Sci. USA. 95:1998;499-504.
19. Sager R., Sheng S., Pemberton P., Hendrix M.J. Maspin. A tumor suppressing serpin. Adv. Exp. Med. Biol. 425:1997;77-88.
20. Sheng S., Carey J., Seftor E.A., Dias L., Hendrix M.J., Sager R. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc. Natl. Acad. Sci. USA. 93:1996;11669-11674.
21. Zou Z., Anisowicz A., Hendrix M.J., Thor A., Neveu M., Sheng S., Rafidi K., Seftor E., Sager R. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science. 263:1994;526-529.
22. Seftor R.E.B., Seftor E.A., Sheng S., Pemberton P.A., Sager R., Hendrix M.J.C. Maspin suppresses the invasive phenotype of human breast carcinoma. Cancer Res. 58:1998;5681-5685.
23. Xie K., Huang S., Dong Z., Juang S.H., Gutman M., Xie Q.W., Nathan C., Fidler I.J. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J. Exp. Med. 181:1995;1333-1343.
24. Xie K., Fidler I.J. Therapy of cancer metastasis by activation of the inducible nitric oxide synthase. Cancer Metastasis Rev. 17:1998;55-75.
25. Gustafsson J. Estrogen receptor-β getting in on the action? Nat. Med. 3:1997;493-494.
26. Tsai M.J., O'Malley B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63:1994;451-486.
27. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA. 93:1996;5925-5930.
28. Mosselman S., Dijkema R., Polman J. ER beta: Identification and characterization of a novel human estrogen receptor. FEBS Lett. 392:1996;49-53.
29. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J., Kushner P.J., Scanlan T.S. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science. 277:1997;1508-1510.
30. Jordan V.C., Morrow H. Tamoxifen, raloxifene, and the prevention of breast cancer. Endoc. Rev. 20:1999;253-278.
31. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., Wolmark N. other National Surgical Adjuvant-Breast and Bowel Project Investigators, Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90:1998;1371-1388.
32. Langan-Fahey S.M., Tormey D.C., Jordan V.C. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur. J. Cancer. 26:1990;883-888.